Does Quality of Life Improve in Multiple Sclerosis Patients Treated Wi
Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®)
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
The primary objective of this study is to evaluate the correlation between the MS Functional Composite Index and two Quality of Life scales (MS Quality of Life 54 and AMS Quality of Life) in patients treated with interferon beta-1a (AVONEX®).
screening, Day -30, Day -1, Months 3, 6, 12, 18, and 24
Quality of life (reported by participants)Immune response
Other measures (3)
Reproducibility of Quality of Life scales per language version
months 18 and 24
Quality of life (reported by participants)Reliability of the Quality of Life scales per language version
months 18 and 24
Quality of life (reported by participants)EDSS score throughout the study
screening, Day -1, Months 12 and 24
Disability progression
Who could take part
Relapsing MS · 18 to 70
Show the full criteria
Inclusion criteria
* Relapsing Remitting Multiple Sclerosis * Interferon naïve * Eligible for interferon beta-1a (AVONEX®) therapy as per Summary of Product Characteristics: * Subject has had relapsing MS for > 1 year * Subject has had experienced 2 exacerbations in the last 2 years * Subject had an EDSS [5] score of \< 5.5 * Subject was ambulant
Exclusion criteria
* Diagnosis of MS defined as progressive * History of any significant cardiac, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude therapy with interferon beta * History of severe allergic or anaphylactic reactions or history of hypersensitivity to human albumin * History of seizures within the 3 months prior to starting this study * History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen or other NSAIDs, that would preclude use of at least one of these during the study * History of intolerance to interferons * Previous use of interferon beta * Female subjects who were pregnant or breast-feeding * For female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study was to find out if patients with Relapsing Remitting Multiple Sclerosis treated with Interferon beta-1a had an improved quality of life after treatment with Interferon beta-1a
Papers
Loading reviews and guidelines…
Related trials
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Phase 3 · Not yet recruiting
Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting
Still running
- Discontinuation of first-line disease modifying treatment (DMT) in lon
Phase 4 · Stopped early
Stopped
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
- Study to Investigate Pregnancy Outcomes in Female Participants Exposed
Completed
Paper found, not read
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017
Phase 3 · Running, not recruiting
Still running
History
Started
Nov 1999
Finished
Feb 2004